| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Operating expenses: | |||||||||
Product revenues, net | |||||||||
- | - | - | - | - | - | 0 | - | - | - |
License and collaboration revenues | |||||||||
- | - | - | - | - | - | 47,786 | - | - | - |
Collaboration revenues | |||||||||
- | - | - | - | - | 92,296 | 47,786 | 48,921 | 34,215 | 20,305 |
Cost of revenues | |||||||||
- | - | - | - | - | - | 0 | - | - | - |
Research and development expenses | |||||||||
11,100 | 49,974 | 67,314 | 109,565 | 121,033 | 103,310 | 147,139 | 125,858 | 100,630 | 58,278 |
General and administrative expenses | |||||||||
16,169 | 15,601 | 28,452 | 32,052 | 24,048 | 18,766 | - | 15,805 | 14,454 | 11,381 |
Gain on deconsolidation of Silver Creek Pharmaceuticals, Inc. | |||||||||
- | - | 10,848 | - | - | - | - | - | - | - |
Gain on sale of assets | |||||||||
4,910 | - | 1,703 | - | - | - | - | - | - | - |
Total operating (income) expenses | |||||||||
22,359 | 65,575 | 95,766 | - | - | - | - | - | - | - |
General and administrative expenses | |||||||||
- | - | - | - | - | - | 21,187 | - | - | - |
Restructuring expenses | |||||||||
- | - | - | 5,710 | - | - | - | - | - | - |
Contingent consideration | |||||||||
- | - | - | - | - | - | - | - | - | 178 |
Total costs and expenses | |||||||||
- | - | - | 147,327 | 145,081 | 122,076 | 168,326 | 141,663 | 115,084 | 69,481 |
Income (loss) from operations | |||||||||
-22,359 | -65,575 | -95,766 | -147,327 | -145,081 | -29,780 | -120,540 | -92,742 | -80,869 | -49,176 |
Other income and expenses: | |||||||||
Interest income | |||||||||
777 | 1,299 | 895 | 276 | 99 | 114 | 166 | 184 | 56 | 74 |
Interest expense | |||||||||
1,528 | 956 | 34,650 | 22,449 | 18,769 | 18,230 | 10,938 | 553 | 13 | 3,726 |
Other expense, net | |||||||||
370 | -3,230 | -1,433 | -8 | 917 | 813 | 627 | 1,357 | 1,150 | 2,669 |
Total other income and expenses | |||||||||
-381 | -2,887 | -22,637 | - | - | - | - | - | - | - |
Net loss from continuing operations before income tax benefit | |||||||||
-22,740 | -68,462 | -118,403 | -169,508 | -162,834 | -47,083 | - | - | - | - |
Income tax benefit | |||||||||
-1,473 | -7,695 | -42,399 | -13,224 | -11,215 | - | - | - | - | - |
Net loss from continuing operations | |||||||||
-21,267 | -60,767 | -76,004 | -156,284 | -151,619 | -47,083 | - | - | - | - |
Discontinued operations: | |||||||||
Income from discontinued operations, net of tax | |||||||||
3,935 | 20,261 | 546,872 | 2,766 | 3,832 | -36,476 | - | - | - | - |
Net (loss) income | |||||||||
- | - | 470,868 | -153,518 | -147,787 | -83,559 | -130,685 | -91,754 | -79,676 | -50,159 |
Net loss attributable to non-controlling interest | |||||||||
- | - | -1,160 | -1,778 | 170 | -268 | 240 | -477 | -453 | -55 |
Net income (loss) | |||||||||
-17,332 | -40,506 | 472,028 | -151,740 | -147,957 | -83,291 | -130,925 | -91,277 | -79,223 | -50,104 |
Net loss from continuing operations | |||||||||
- | - | -74,844 | -154,506 | -151,789 | -46,815 | - | - | - | - |
Income from discontinued operations, net of tax | |||||||||
- | - | 546,872 | 2,766 | 3,832 | -36,476 | - | - | - | - |
Net loss | |||||||||
-17,332 | -40,506 | 472,028 | -151,740 | -147,957 | -83,291 | -130,925 | -91,277 | -79,223 | -50,104 |
Other comprehensive income: | |||||||||
Unrealized gain on marketable securities | |||||||||
9 | -9 | - | - | 74 | -50 | 14 | -38 | - | - |
Other comprehensive income | |||||||||
9 | -9 | - | - | 74 | -50 | 14 | -38 | - | - |
Comprehensive income (loss) | |||||||||
-17,323 | -40,515 | 472,028 | -151,740 | -147,883 | -83,341 | -130,911 | -91,315 | -79,223 | -50,104 |
Basic and dilutive net loss per common share | |||||||||
Net loss from continuing operations | |||||||||
-1.59 | -4.55 | -5.66 | -12.33 | -13.63 | -4.49 | - | - | - | - |
Net income from discontinued operations, net of tax | |||||||||
0.29 | 1.52 | 41.33 | 0.22 | 0.34 | -3.49 | - | - | - | - |
Net income (loss) per common share - basic and diluted | |||||||||
-1.30 | -3.03 | 35.67 | -12.11 | -13.29 | -7.98 | -1.32 | -1.28 | -7.67 | -5.57 |
Weighted-average common shares used to compute basic and diluted net loss per common share | |||||||||
13,353 | 13,343 | 13,232 | 12,533 | 11,136 | 10,441 | 98,919 | 72,831 | 11,343 | 10,994 |
Cash dividends paid per common share | |||||||||
2.00 | - | - | - | - | - | - | - | - | - |